Ketamine for Treatment of Alzheimers Disease Related Depression
NCT07943741 · KeTADiD · Vanderbilt University Medical Center
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Feasibility of the Study as Measured by the Number of Participants Completing the Study
Measured over From enrollment to the end of safety monitoring at 8 weeks
Safety, as Measured by the Number of Participants with At Least One Treatment-Emergent Adverse Event
Measured over From the first medication infusion through study completion at 8 weeks
Clinician-Administered Dissociative States Scale (CADSS) Total Score
Measured over Week 1 Infusion 1, Week 1 Infusion 2, Week 2 Infusion 1, and Week 2 Infusion 2 prior to and 40 and 90 minutes after the start of each infusion.
Severity of Suicidal Thoughts with Montgomery-Åsberg Depression Rating Scale (MADRS) Item 10 Score
Measured over From enrollment to the end of safety monitoring at 8 weeks
Change in Severity of Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Measured over Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Change in Suicidal Behavior as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Measured over Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Number of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
Measured over Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Severity of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
Measured over Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)
Measured over Week 4 (approximately 2 weeks after the final medication infusion)
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Vanderbilt Psychiatric Hospital | Nashville | Tennessee | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT07943741 on ClinicalTrials.gov →
Last updated in the registry 2026-11-17. Registry records change; this page reflects the data build of 2026-11-17.
Related